Key result
GDF-15 and hs-TnT predict cardiovascular events in early diabetes, while NT-proBNP predicts longstanding disease risk.
Why the study?
Based on the complex pathophysiology of type 2 diabetes and atherosclerosis, dynamic changes in the prognostic value of cardiovascular biomarkers over time were hypothesized.
Observational (n=746)
Yes
Effect estimate: HR 1.53 (95% CI 1.30-1.80)
p-value: p=<0.01
The prognostic power of cardiovascular biomarkers changes dynamically with the duration of type 2 diabetes, with markers of inflammation and subclinical dysfunction (GDF-15, hs-TnT) performing better early on, and markers of advanced organ dysfunction (NT-proBNP) performing better in longstanding disease.
May inform duration-tailored risk stratification in type 2 diabetes; leaves open prospective validation before practice change.
Background: Based on the complex pathophysiology of type 2 diabetes and atherosclerosis we hypothesized a dynamic change in prognostic value of cardiovascular biomarkers over time. Methods : In this prospective study 746 patients with type 2 diabetes mellitus, being followed up for 60 months were analysed. The primary endpoint was defined as unplanned hospitalization for cardiovascular disease or death. Beside others, especially the prognostic performance of the biomarkers of interest (GDF-15, NT-proBNP, hs-TnT) was evaluated in relation to quartiles of diabetesduration. Results: In patients having a diabetes duration below 7 years lnGDF-15 (HR 2.84; p < 0.01) and lnhs-TnT (HR 2.96; p<0.01) were significant predictors of the primary endpoint. LnAge (HR 40.11; p < 0.01) and lnNT-proBNP (HR 1.61; p <0.01) were significant predictors in patients with a diabetes duration between 7 and 12 years. In the third quartile (diabetes duration 12-22 years) lnAge (HR 13.09; p =0.041), urinary albumin to creatinine ratio (HR 2.74; p = 0.001) and lnNT-proBNP (HR 1.81, p < 0.001) predicted the endpoint. In patients with a diabetes duration above 22 years, lnAge (HR 50.79; p = 0.002) and lnNT-proBNP (HR 2.1; p < 0.01) were the only significant predictors of the endpoint. Conclusion: Prognostic power of cardiovascular biomarkers changes dynamically in relation to duration of type 2 diabetes mellitus. In patients with shorter duration of the disease markers of subclinical cardiovascular dysfunction and inflammation perform better than markers of systemic advanced organ dysfunction and cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Resl et al. (2020) conducted an observational in Type 2 diabetes mellitus (n=746). Cardiovascular biomarkers (NT-proBNP, GDF-15, hs-TnT) was evaluated on Composite of unplanned hospitalization for cardiovascular causes or all-cause mortality (HR 1.53, 95% CI 1.30-1.80, p=<0.01). The prognostic value of cardiovascular biomarkers changed dynamically, with GDF-15 and hs-TnT predicting cardiovascular events in early diabetes (<7 years) and NT-proBNP predicting events in longstanding disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: